At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions
In Brief
A clinical study evaluating Verapamil and Placebo for Coronary Disease and Verapamil Toxicity. Completed, enrolled 591 participants across 1 site.
Detailed Summary
Background Verapamil is traditionally applied prophylactically in transradial procedures to prevent radial artery spasm. However, verapamil may have side effects and is contraindicated in some clinical settings. Methods: During an investigator-initiated, randomized, double-blind trial, we evaluate the need for preventive verapamil administration. After vascular access is established, patients receive either 5 mg verapamil (n=297) or placebo (n=294). We compare the rate of access site conversions as primary end point using a superiority margin of 5%. Occurrence of code breaks (composite of conversions and unplanned use of verapamil), overall verapamil use, procedural and fluoroscopic times, contrast volume, and subjective pain are investigated as secondary end points.
Study Details
Timeline
Interventions
Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
Intraarterial administration of 10 mL saline.